FMP
Cellectar Biosciences, Inc.
CLRB
NASDAQ
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
0.303 USD
0.0126 (4.16%)
CLRB Financial Statements
Year
2024
2023
2022
2021
Total Revenue
0
0
0
0
Cost of Revenue
0
192.38k
238.87k
227.64k
Gross Profit
0
-192.38k
-238.87k
-227.64k
Operating Expenses
51.78M
38.96M
28.81M
24.13M
Research and Development
26.14M
27.27M
19.22M
17.59M
Selling, General & Administrative Expenses
25.64M
11.69M
9.59M
6.54M
Selling & Marketing Expenses
0
945.18k
0
0
General & Administrative Expenses
25.64M
10.75M
9.59M
6.54M
Other Expenses
0
-0
0
6.63k
Operating Income
-51.78M
-38.96M
-28.81M
-24.13M
Total Other Income/Expenses Net
7.26M
917.15k
152.52k
8.92k
Income Before Tax
-44.52M
-38.04M
-28.66M
-24.12M
Income Tax
66k
-60k
-60k
-152.2k
Net Income
-44.58M
-37.98M
-28.6M
-23.97M
Basic EPS
-1.22
-3.11
-4.05
-4.32
EPS Diluted
-1.2
-3.11
-4.05
-4.32
Basic Average Shares
36.62M
12.22M
7.06M
5.55M
Diluted Average Shares
37.14M
12.22M
7.06M
5.55M
EBITDA
-51.78M
-38.77M
-28.67M
-23.98M
All figures are in USD.
